In a 2012 meeting, the FDA voted to allow the use of human fetal cells and adult human tumor cells in vaccines, despite acknowledging the many risks, including that vaccine recipients might later develop cancer.

FDA allows both human fetal cells and adult human tumor cells in vaccines. Both types have cancer risks. While both Pfizer and Moderna tested their mRNA vaccine using fetal cells, there are no fetal cells, cell debris or DNA in their final products.

However, according to company documents, Johnson and Johnson (Janssen) and Altimmune’s COVID vaccines are manufactured in the human fetal cell line PER-C6, and thus the final vaccine products will contain cellular debris and DNA fragments from these cells. Researchers harvested these cell lines from the eyeball of an 18-week-old human fetus aborted in 1985, and then rendered them immortal by making them cancerous.

The AstraZeneca, Cansino, Gamayela, Vaxart, LongComm and Upitt vaccines are manufactured in the human fetal cell line HEK293, and thus the final vaccine products will contain cellular debris and DNA fragments from the fetal HEK-293 cell line. Scientists harvested this cell line from the kidney of a female Dutch fetus legally aborted in 1973 and then immortalized the cells by rendering them cancerous.

Normal primary cells, which are unable to replicate indefinitely, ultimately die. Immortalized cell lines are derived from known malignant cancer cells such as those obtained from Henrietta Lacks (HeLa) or created in the laboratory by introducing viral oncogenes or chemical exposures capable of mutating normal primary cells into immortal tumor cells.

According to FDA’s “The Pink Sheet” dated Nov. 29, 1999, for two decades the agency has been acutely aware of the inherent risks of using immortalized cell lines for vaccine development. The FDA CBER Director Dr. Peter Patriarca, M.D. explained that continuous cell lines are used for their ability to self-propagate, making them an ideal substrate on which to grow viruses, “the worst thing we are concerned about is …  malignancy, because some of these continuous cells have the potential for growing tumors in laboratory animals.”

Patriarca further conceded that “the technology to make these vaccines actually exceeds the science and technology to understand how these vaccines work and to predict how they will work.” This dire “black box” conundrum that Patriarca described in 1999 is even more acute today with the urgent pressure to develop COVID vaccines before manufacturers have tested them in animals or subjected them to long-term safety studies.

We call vaccines “biologics” because vaccinologists have traditionally grown their antigens on biological substrates — usually animal tissue. Competing companies culture COVID vaccines on a variety of animal strata. The Merck and IAVA COVID vaccines are manufactured in vero monkey cells, and thus contain cellular debris and DNA fragments from vero monkeys in the final product. The Sanofi, GSK, and Novavax COVID jabs are manufactured in insect cells and thus contain insect cellular debris and DNA fragments in the final products.

Public health advocates criticize the use of animal tissues in vaccines due to risks that they carry endogenous viruses, microbes, parasites and lack safety testing. (Plague of Corruption, Mikovits 2020).The first use of human fetal cells in vaccines occurred around 60 years ago, but the practice is increasingly popular. It was always controversial. Immunologists long considered using cells from aborted human fetuses in vaccines to be a high-risk gambit; human DNA debris is much more likely to infiltrate cells in vaccinated individuals than insect or monkey DNA.

Researchers and regulatory agencies have worried for more than 50 years about the potential for injected DNA to cause cancer. According to Dr. Theresa Deisher, a research scientist, primitive (unmethylated) DNA chains from human fetuses have the ability to 1) activate immune receptors that could lead to autoimmune attacks in susceptible individuals who have genetic predispositions that cause their own DNA to be under-methylated, or 2) insert into cells where they could combine with host DNA and cause mutations.

Regulators have in the past predicted that the odds of that happening were less than 1 in a trillion. However, in early gene therapy trials this event did indeed occur in 4 of 9 boys, 1 of whom died from the leukemia the insertions caused.

“Researchers have long observed that when introduced DNA enters a cell, it chooses a region of the cell that gives it a survival advantage. These could be the regions that are most likely to produce long-living cancer cells,” Dr. Deisher told me. FDA has never made any effort to test the safety of this practice or to determine whether the epidemic of soft-tissue cancers is “vaccine-generation” children is related to the use of cancerous fetal cells in vaccines. Even worse, in 2002, FDA green-lighted vaccine companies to use cancerous tumor cells from adults in vaccines.

FDA as an arm of Big Pharma

Before reviewing the shocking transcript of the FDA meeting that approved this dubious practice, we need to understand the conflicts and corruption that pervade this rogue agency. If we are to ever develop safe, effective COVID vaccines, we need first to stop thinking of the FDA as a regulatory agency; it is an arm of the notoriously corrupt pharmaceutical industry.

According to a 2017 Emory University study entitled “Thick as Thieves? Big Pharma Wields Its Power with the Help of Government Regulation,” FDA bureaucrats act as “enablers, or perhaps worse still, [they are] complicit in questionable or ethically unsound activity as a result of being driven by self-serving motives ….” A 1992 law that allows drugmakers to buy fast-track approvals for new products from FDA has poured concrete on a regulatory dynamic already corrupted by all the ubiquitous mechanisms of “agency capture.”

Between 2000 and 2010, pharmaceutical companies paid the FDA $3.4 billion to gain rapid drug approvals. Today, Pharma companies underwrite three-quarters of FDA’s budget for scientific reviews (ProPublica) and fund nearly 50% of the FDA’s total annual budget through PDUFA fees. In exchange, the agency increasingly fast-tracks expensive drugs and vaccines with significant side effects and unproven health benefits.

No one at FDA wins kudos for slowing down those money flows. To the contrary, according to FDA’s own employees, drug company payments bias regulators, with “an inclination toward approval.”

According to Dr. Michael Carome, a former Health and Human Services (HHS) official and a director of the advocacy group Public Citizen, “Instead of a regulator and a regulated industry, we now have a partnership … That relationship has tilted [the FDA] away from a public health perspective to an industry friendly perspective.”